Mantle cell lymphoma (MCL) accounts for 5-10% of non-Hodgkin's lymphomas and it bears the worst prognosis among B cell lymphomas. Even more than in the other lymphomas, new insights in MCL biology are needed. In this review we will discuss the most recent published data. Immunoglobulin sequencing da
Update on the molecular biology of malignant mesothelioma
β Scribed by Amie Y. Lee; Dan J. Raz; Biao He; David M. Jablons
- Publisher
- John Wiley and Sons
- Year
- 2007
- Tongue
- English
- Weight
- 166 KB
- Volume
- 109
- Category
- Article
- ISSN
- 0008-543X
No coin nor oath required. For personal study only.
β¦ Synopsis
Abstract
Malignant mesothelioma (MM) is a highly aggressive tumor with a very poor prognosis. The disease is largely unresponsive to conventional chemotherapy or radiotherapy, and most patients die within 10β17 months of the first symptoms. Novel, more effective therapeutic strategies are needed for this inexorably fatal disease. Improvement in our understanding of the molecular biology of MM has identified promising new candidates for targeted treatments. In this review the key molecular signaling pathways, including vascular endothelial growth factor (VEGF), epidermal growth factor (EGF), Wnt, and the cell cycle control genes p53, pRb, and bclβ2 that appear to play an important role in the pathogenesis of MM are explored. Cancer 2007. Β© 2007 American Cancer Society.
π SIMILAR VOLUMES
Background and Objectives: Primary Diffuse Malignant Peritoneal Mesothelioma is a rare disease, with an incidence of 2.2 cases in 1.000.000 in the USA. It occupies 10% of all mesotheliomas referred in literature. Methods: We describe a case of diffuse malignant peritoneal mesothelioma arising in a 5
BioMoleculesAlive.org is a collection of digital resources sponsored by the American Society for Biochemistry and Molecular Biology. It is part of a larger effort called the BioSciEdNet (BEN) initiative (www.biosciednet.org). The collection will include resources in five areas: software, visual reso